Clinical trial phases 1, 2 and 3: what each one proves
Published October 26, 2026. General explainer with examples from this site's news articles.
Quick take: each phase answers a different question. Knowing which phase a headline is about tells you how much to trust it.
The three phases
| Phase | Main question | Typical size |
|---|---|---|
| 1 | Is it safe enough to keep testing? | Small |
| 2 | Is there a signal, and what dose? | Medium |
| 3 | Does it work and stay safe in a large group, compared with a control? | Large |
Real examples
- Phase 3: retatrutide's TRIUMPH-1 enrolled 2,339 people for 80 weeks, randomized, double blind and placebo controlled. See the results.
- Phase 3 starting: Viking's oral program planned two trials of 560 people each, running 68 weeks, with results over a year away.
What phase 3 still does not settle
- Company reported results are not independent.
- Trials describe selected people, not everyone.
- Regulators still have to review, and approval is a separate step.
Two words worth knowing
Randomized means chance decides who gets what. Placebo controlled means one group gets an inactive comparison, so effects can be compared fairly.
More checks: how to read peptide news.
Ready to order?
Paste it in the Promo code box in the order summary at checkout, then press Apply. Confirm the discount line before you pay.
Common questions
What does phase 1 test?
Mainly safety in a small group.
Is phase 3 the end?
No. Regulators still review the results before approval.
What does placebo controlled mean?
One group receives an inactive comparison so results can be compared fairly.
Sources
- AJMC: Retatrutide phase 3 TRIUMPH-1 results (May 21, 2026)
- REX Shares: The Peptide Market Update, a two-drug story starts to widen (Oct 2026)
Summarised in my own words. Read the originals for the full detail.